Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.2%

1 terminated out of 46 trials

Success Rate

94.7%

+8.2% vs benchmark

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

33%

6 of 18 completed with results

Key Signals

6 with results95% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (7)
P 1 (9)
P 2 (9)
P 3 (3)

Trial Status

Completed18
Unknown14
Recruiting9
Active Not Recruiting2
Terminated1
Withdrawn1

Trial Success Rate

94.7%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT03556384Phase 2Completed

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

NCT05957367Phase 1RecruitingPrimary

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT06640361Phase 3RecruitingPrimary

A Study of Olverembatinib in SDH-deficient GIST.

NCT07697248RecruitingPrimary

LRG GIST Patient Registry

NCT07406633Phase 2Recruiting

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT06441331Phase 1Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT07411118Not ApplicableRecruiting

RCT of EFTR Versus STER for GIST Treatment

NCT05734105Phase 3Active Not RecruitingPrimary

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT06208748Phase 2Active Not Recruiting

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

NCT07096609Phase 1Not Yet RecruitingPrimary

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

NCT05443087Not ApplicableRecruiting

TARGETed Therapy Drug MONITOring in DIGestive Oncology

NCT05804331Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

NCT04908176Phase 1Completed

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04599660CompletedPrimary

Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)

NCT04927260UnknownPrimary

French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients

NCT05474794Not ApplicableUnknown

Detective Flow Imaging Endoscopic Ultrasonography in Subepithelial Lesions

NCT01376505Phase 1Completed

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT05895942UnknownPrimary

Exploring the Molecular Mechanism Based on KIT Mutation

NCT04138381Phase 1Unknown

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Scroll to load more

Research Network

Activity Timeline